Annals On Call - Oral Pharmacologic Therapy in Type 2 Diabetes: Choosing Therapy Wisely
Authors: Robert M. Centor, Michael J. Barry
Journal: Annals of Internal Medicine (2018)

Web Exclusives18 September 2018Annals On Call - Oral Pharmacologic Therapy in Type 2 Diabetes: Choosing Therapy WiselyFREERobert M. Centor, MD and Michael J. Barry, MDRobert M. Centor, MDHuntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Search for more papers by this author and Michael J. Barry, MDMassachusetts General Hospital, Boston, Massachusetts (M.J.B.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/A18-0004 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail In this episode of Annals On Call, Dr. Centor interviews Dr. Michael J. Barry about the evidence for choosing oral drug therapy for patients with type 2 diabetes from among the expanding list of options.Annals articles discussed include...Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians: http://annals.org/aim/fullarticle/2595888/oral-pharmacologic-treatment-type-2-diabetes-mellitus-clinical-practice-guidelineGlycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind: http://annals.org/aim/fullarticle/2595896/glycemic-therapy-type-2-diabetes-choices-expand-data-lag-behindAbout Annals On CallAnnals On Call focuses on a clinically influential article published in Annals of Internal Medicine. Dr. Robert Centor shares his own perspective on the material and interviews topic area experts to discuss, debate, and share diverse insights about patient care and health care delivery.For more information on Annals On Call and for more episodes, visit go.annals.org/OnCall. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Huntsville Regional Medical Campus, University of Alabama Birmingham School of Medicine, Birmingham, Alabama (R.M.C.)Massachusetts General Hospital, Boston, Massachusetts (M.J.B.)Disclosures: Dr. Centor has disclosed the following: Honoraria: Medscape. Dr. Barry has disclosed the following: Employment: Informed Medical Decisions Foundation/Healthwise and Massachusetts General Hospital.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Proctor & Gamble, Pfizer, and Johnson & Johnson. Previousarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoOral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians Amir Qaseem , Michael J. Barry , Linda L. Humphrey , Mary Ann Forciea , and Glycemic Therapy for Type 2 Diabetes: Choices Expand, Data Lag Behind Judith E. Fradkin and Griffin P. Rodgers Metrics Cited byThe Gout WarsBurton Abrams, MS 18 September 2018Volume 169, Issue 6Page: OC1KeywordsDiagnostic techniquesDisclosureDrug therapyHealth careOral medicinePatientsTreatment guidelinesType 2 diabetes ePublished: 18 September 2018 Issue Published: 18 September 2018 Copyright & PermissionsCopyright © 2018 by American College of Physicians. All Rights Reserved.Loading ...